|
|
Volumn 18, Issue 9, 2012, Pages 1310-
|
|
Lack of BRCA testing approval creates snag for cancer trials
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRCA1 PROTEIN;
DOXORUBICIN;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;
OLAPARIB;
RUCAPARIB;
VELIPARIB;
ANTINEOPLASTIC AGENT;
BREAST CANCER;
CANCER SCREENING;
DNA REPAIR;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
EXPERT WITNESS;
FOOD AND DRUG ADMINISTRATION;
GENE MUTATION;
HEALTH CARE COST;
HUMAN;
LAW SUIT;
NOTE;
OVARY CANCER;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
BREAST TUMOR;
CLINICAL TRIAL (TOPIC);
DRUG ANTAGONISM;
FEMALE;
GENETICS;
OVARY TUMOR;
PATENT;
TUMOR SUPPRESSOR GENE;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CLINICAL TRIALS AS TOPIC;
FEMALE;
GENES, BRCA1;
GENES, BRCA2;
HUMANS;
OVARIAN NEOPLASMS;
PATENTS AS TOPIC;
POLY(ADP-RIBOSE) POLYMERASES;
|
|
EID: 84868651136
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm0912-1310a Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
